uniQure (NASDAQ:QURE) Receives Average Rating of “Buy” from Brokerages

Shares of uniQure (NASDAQ:QUREGet Rating) have been assigned an average recommendation of “Buy” from the fourteen analysts that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $53.38.

QURE has been the topic of a number of analyst reports. Stifel Nicolaus decreased their price objective on uniQure from $66.00 to $37.00 in a research note on Thursday, May 5th. StockNews.com lowered uniQure from a “hold” rating to a “sell” rating in a research note on Monday. Truist Financial decreased their price objective on uniQure from $90.00 to $51.00 in a research note on Wednesday, April 13th. UBS Group raised uniQure from a “neutral” rating to a “buy” rating and set a $40.00 price objective on the stock in a research note on Thursday, March 17th. Finally, Chardan Capital decreased their price target on uniQure from $95.00 to $65.00 in a research note on Wednesday, March 30th.

uniQure stock traded up $0.45 during trading hours on Tuesday, hitting $13.93. The stock had a trading volume of 2,239 shares, compared to its average volume of 531,876. The company has a quick ratio of 17.09, a current ratio of 12.94 and a debt-to-equity ratio of 0.19. The company has a market cap of $649.81 million, a PE ratio of 2.06 and a beta of 1.13. uniQure has a 1-year low of $13.35 and a 1-year high of $38.80. The firm has a fifty day simple moving average of $16.96.

uniQure (NASDAQ:QUREGet Rating) last posted its quarterly earnings data on Monday, May 2nd. The biotechnology company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.07). uniQure had a net margin of 61.76% and a return on equity of 54.85%. On average, research analysts expect that uniQure will post -3.29 EPS for the current fiscal year.

In other news, VP Alexander Edward Kuta III sold 3,405 shares of the firm’s stock in a transaction dated Monday, February 28th. The stock was sold at an average price of $16.72, for a total value of $56,931.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Christian Klemt sold 4,075 shares of the firm’s stock in a transaction dated Monday, February 28th. The stock was sold at an average price of $16.80, for a total value of $68,460.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 19,954 shares of company stock worth $333,630. Company insiders own 2.66% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Hudson Bay Capital Management LP raised its holdings in shares of uniQure by 12.5% during the 3rd quarter. Hudson Bay Capital Management LP now owns 260,000 shares of the biotechnology company’s stock valued at $8,323,000 after buying an additional 28,900 shares during the period. American Century Companies Inc. purchased a new stake in shares of uniQure during the 3rd quarter valued at about $1,062,000. Handelsbanken Fonder AB raised its holdings in shares of uniQure by 55.3% during the 3rd quarter. Handelsbanken Fonder AB now owns 11,800 shares of the biotechnology company’s stock valued at $378,000 after buying an additional 4,200 shares during the period. Two Sigma Investments LP purchased a new stake in shares of uniQure during the 3rd quarter valued at about $3,036,000. Finally, Banque Pictet & Cie SA purchased a new stake in shares of uniQure during the 4th quarter valued at about $1,576,000. Institutional investors and hedge funds own 81.35% of the company’s stock.

uniQure Company Profile (Get Rating)

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

Featured Articles

Analyst Recommendations for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.